More extensive use of the JAK1/JAK2 inhibitor ruxolitinib is associated with a greater risk of mycobacterial infections (Mycobacterium tuberculosis and atypical mycobacterial infections) in the treatment of patients with myelofibrosis and polycythemia vera (64, 65). This evidence concerns the gene JAK1 and myelofibrosis.